6 results on '"Jinlu Dai"'
Search Results
2. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer
- Author
-
Evan T. Keller, Jian Zhang, Mikio Namiki, You Qiang Li, Jinlu Dai, Kazutaka Narimoto, Atsushi Mizokami, Kouji Izumi, and Takashi Shima
- Subjects
Pathology ,medicine.medical_specialty ,Gene knockdown ,biology ,business.industry ,Urology ,Cancer ,medicine.disease ,chemistry.chemical_compound ,Prostate cancer ,Oncology ,Paclitaxel ,chemistry ,Cell culture ,medicine ,Cancer research ,biology.protein ,Tensin ,Immunohistochemistry ,Epidermal growth factor receptor ,business - Abstract
BACKGROUND. Recently, we established paclitaxel-resistant prostate cancer cell lines (PC-3-TxR and DU145-TxR). To determine the mechanisms of paclitaxel resistance in PC-3TxR cells, we compared the gene expression profiles between PC-3 and PC-3-TxR cells. Our results indicated that expression of the C-terminal tensin like protein (CTEN, tensin 4) gene was down-regulated by 10-fold in PC-3-TxR cells. We investigated the possibility that CTEN overexpression restores paclitaxel sensitivity. METHODS. We investigated how knockdown and overexpression of CTEN in androgenindependent cell lines affect paclitaxel sensitivity by colony formation assay and growth inhibition assay. To determine the mechanisms by which CTEN affects paclitaxel sensitivity, we investigated the relationships between CTEN and F-actin or epidermal growth factor receptor (EGFR) in PC-3 cells. We also examined the association between expression of CTEN and grade of prostate cancer by immunohistochemistry using tissue microarray analysis. RESULTS. Down-regulation of CTEN, which is located in the cytoskeleton, played an important role in paclitaxel resistance in PC-3-TxR cells. Knockdown of CTEN expression in PC-3 cells induced paclitaxel resistance. Overexpression of CTEN in PC-3-TxR and DU145-TxR cells restored paclitaxel sensitivity. CTEN expression was inversely correlated with F-actin and EGFR expression. Then knockdown of actin and EGFR in PC-3-TxR cells recovered paclitaxel sensitivity, indicating that CTEN down-regulation mediates paclitaxel resistance through elevation of EGFR and actin expression. Moreover, CTEN expression was inversely correlated with Gleason score. CONCLUSIONS. These results strongly suggested that CTEN plays an important role in paclitaxel sensitivity and that CTEN expression level may be a prognostic predictive factor for PCa patients. Prostate 70: 48–60, 2010. # 2009 Wiley-Liss, Inc.
- Published
- 2009
3. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model
- Author
-
A. Lui, Stephanie Daignault, Evan T. Keller, E. E. Sargent, June Escara-Wilke, Mark L. Day, K. M. Woods Ignatoski, William C. Dougall, Jian Zhang, Zhi Yao, and Jinlu Dai
- Subjects
musculoskeletal diseases ,Male ,medicine.medical_specialty ,Recombinant Fusion Proteins ,Urology ,Bone Neoplasms ,Docetaxel ,Mice, SCID ,urologic and male genital diseases ,Bone and Bones ,Article ,Mice ,Prostate cancer ,Prostate ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Adjuvant therapy ,Animals ,Adjuvants, Pharmaceutic ,Dose-Response Relationship, Drug ,biology ,Bone cancer ,business.industry ,RANK Ligand ,Prostatic Neoplasms ,Bone metastasis ,Cancer ,medicine.disease ,Radiography ,Disease Models, Animal ,medicine.anatomical_structure ,Endocrinology ,Oncology ,Chemotherapy, Adjuvant ,RANKL ,Cancer research ,biology.protein ,Taxoids ,business ,medicine.drug - Abstract
BACKGROUND. Docetaxel induces an anti-tumor response in men with advanced prostate cancer (PCa); however, the side effects associated with docetaxel treatment can be severe, resulting in discontinuation of therapy. Thus, identification of an effective adjuvant therapy to allow lower doses of docetaxel is needed. Advanced PCa is typically accompanied by skeletal metastasis. Receptor activator of NFkB ligand (RANKL) is a key pro-osteoclastic factor. Targeting RANKL decreases establishment and progression of PCa growth in bone in murine models. METHODS. The efficacy of inhibiting RANKL, using a recombinant soluble RANK extracellular domain fused with the immunoglobulin Fc domain (RANK-Fc), was tested as an adjuvant therapy with docetaxel for PCa bone metastasis in a murine intra-tibial model. RESULT. The combination of RANK-Fc and docetaxel reduced tumor burden in bone greater than either treatment alone. CONCLUSION. The combination of docetaxel with a RANKL-inhibiting agent merits further investigation for treatment of advance PCa. Prostate 68: 820–829, 2008. # 2008 Wiley-Liss, Inc.
- Published
- 2008
4. Skeletal Localization and Neutralization of the SDF-1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo
- Author
-
Jianhua Wang, Yan Xi Sun, A. J. Koh-Paige, Hyusuk Shim, Abraham Schneider, Evan T. Keller, Laurie K. McCauley, Jinlu Dai, Kevin Cook, Kenneth J. Pienta, Younghun Jung, Russell S. Taichman, Jingcheng Wang, and Nadir I. Osman
- Subjects
Male ,Receptors, CXCR4 ,Pathology ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Mice, Nude ,Bone Marrow Cells ,Bone Neoplasms ,Enzyme-Linked Immunosorbent Assay ,In situ hybridization ,Metaphysis ,CXCR4 ,Bone and Bones ,Metastasis ,Mice ,Prostate cancer ,In vivo ,Cell Line, Tumor ,Animals ,Humans ,Medicine ,Tissue Distribution ,Orthopedics and Sports Medicine ,RNA, Messenger ,Amino Acids ,Neoplasm Metastasis ,In Situ Hybridization ,Cell Proliferation ,business.industry ,Prostatic Neoplasms ,medicine.disease ,Immunohistochemistry ,Chemokine CXCL12 ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Calcium ,Bone marrow ,Peptides ,business ,Chemokines, CXC ,Neoplasm Transplantation - Abstract
To delineate the role of SDF-1 and CXCR4 in metastatic prostate cancer (CaP), positive correlations were established between SDF-1 levels and tumor metastasis. Neutralization of CXCR4 limited the number and the growth of intraosseous metastasis in vivo. Together, these in vivo metastasis data provide critical support that SDF-1/CXCR4 plays a role in skeletal metastasis. Introduction: Previously we determined that the stromal-derived factor-1 (SDF-1)/CXCR4 chemokine axis is activated in prostate cancer (CaP) metastasis to bone. To delineate the role of SDF-1/CXCR4 in CaP, we evaluated SDF-1 levels in a variety of tissues and whether neutralization of SDF-1 prevented metastasis and/or intraosseous growth of CaPs. Materials and Methods: SDF-1 levels were established in various mouse tissues by ELISA, immunohistochemistry, and in situ hybridization. To assess the role of SDF-1/CXCR4 in metastasis, bone metastases were established by administering CaP cells into the left cardiac ventricle of nude animals in the presence or absence of neutralizing CXCR4 antibody. The effect of SDF-1 on intraosseous growth of CaP cells was determined using intratibial injections and anti-CXCR4 antibodies and peptides. Results: There was a positive correlation between the levels of SDF-1 and tissues in which metastatic CaP lesions were observed. SDF-1 levels were highest in the pelvis, tibia, femur, liver, and adrenal/kidneys compared with the lungs, tongue, and eye, suggesting a selective effect. SDF-1 staining was generally low or undetectable in the center of the marrow and in the diaphysis. SDF-1 mRNA was localized to the metaphysis of the long bones nearest to the growth plate where intense expression was observed near the endosteal surfaces covered by osteoblastic and lining cells. Antibody to CXCR4 significantly reduced the total metastatic load compared with IgG control-treated animals. Direct intratibial injection of tumor cells followed by neutralizing CXCR4 antibody or a specific peptide that blocks CXCR4 also decreased the size of the tumors compared with controls. Conclusions: These data provide critical support for a role of SDF-1/CXCR4 in skeletal metastasis. Importantly, these data show that SDF-1/CXCR4 participate in localizing tumors to the bone marrow for prostate cancer.
- Published
- 2004
5. Mechanisms of Unexplained Anemia in the Nursing Home
- Author
-
Paul J. Drinka, Melvin Gerald, Dean Fergusson, Evan T. Keller, Felix Silverstone, Rex Bidenbender, Anthony Lechich, William B. Ershler, Jinlu Dai, Andrew S. Artz, and Mark A. Mccamish
- Subjects
Geriatrics ,Pediatrics ,medicine.medical_specialty ,education.field_of_study ,Anemia ,business.industry ,Population ,medicine.disease ,Erythropoietin ,hemic and lymphatic diseases ,Cohort ,medicine ,Medical history ,Geriatrics and Gerontology ,education ,Intensive care medicine ,business ,Prospective cohort study ,Cohort study ,medicine.drug - Abstract
OBJECTIVES: To characterize anemia in elderly nursinghome residents.DESIGN: Prospective multiinstitutional cohort study.SETTING: Five nursing homes.PARTICIPANTS: From retrospective analysis, residentsfound to be anemic using chart review were prospectivelyrandomized. Of the 81 residents enrolled, 60 were anemic.MEASUREMENTS: Chart review for medical history andfactors related to treatment or history of anemia, extensivelaboratory evaluation for causes of anemia, and classifica-tion of anemia by two hematologists.RESULTS: Among the 60 anemic residents, the causes ofanemia were idiopathic (n527), iron-deficiency (n514),anemia associated with chronic disease (n58), anemia ofrenal insufficiency (n56), and other (n55). The eryrthro-poietin (EPO) response to anemia was lower in residentswith idiopathic anemia (IA) than in those with iron-deficiency anemia, and this correlated with renal functionas estimated using calculated creatinine clearance. In thiselderly population, advancing age was not correlated withlower EPO response.CONCLUSION: IA is common in nursing home residents.AlowerEPOresponsecontributestothehighprevalenceofanemia in this setting and may be due, in part, to occultrenal dysfunction. J Am Geriatr Soc 52:423–427, 2004.Key words: elderly; anemia; erythropoietin; renal insuffi-ciency; frail
- Published
- 2004
6. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro
- Author
-
Avni H. Patel, Michael D. Morris, Jinlu Dai, Jian Zhang, Emileigh Rohn, Catherine P. Tarnowski, Evan T. Keller, and Din Lii Lin
- Subjects
Male ,Bone sialoprotein ,medicine.medical_specialty ,Spectrophotometry, Infrared ,Bone Morphogenetic Protein 7 ,Urology ,Receptors, Cytoplasmic and Nuclear ,Anthraquinones ,Bone Neoplasms ,Core Binding Factor Alpha 1 Subunit ,Spectrum Analysis, Raman ,Receptors, Tumor Necrosis Factor ,Metastasis ,Prostate cancer ,Osteoprotegerin ,Transforming Growth Factor beta ,Internal medicine ,LNCaP ,Tumor Cells, Cultured ,medicine ,Humans ,Glycoproteins ,Osteoblasts ,Staining and Labeling ,biology ,business.industry ,Calcinosis ,Prostatic Neoplasms ,Bone metastasis ,Osteoblast ,medicine.disease ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Durapatite ,Endocrinology ,medicine.anatomical_structure ,Oncology ,Bone Morphogenetic Proteins ,Cancer research ,biology.protein ,Calcium ,Osteonectin ,business ,Cell Division ,Transcription Factors - Abstract
BACKGROUND Prostate cancer frequently metastasizes to bone. However, unlike many other tumors that produce osteolytic lesions, prostate cancer produces osteoblastic lesions through unknown mechanisms. In the current study, we explored the ability and mechanism of an osteotropic prostate cancer cell line (C4-2B) to induce mineralization. METHODS C4-2B cells were grown in promineralization media. Mineral deposition was characterized using von Kossa staining, calcium retention, alizarin red staining, Raman spectroscopy, and electron microscopy. Expression of osteoblast-related proteins was determined by RT-PCR. The nuclear level of the bone-specific transcription factor Cbfa1 was determined using western analysis and the effect of inhibiting Cbfa1 function, using a “decoy” Cbfa1 response element oligo, on mineralization was determined. RESULTS The studies demonstrated that C4-2B cells, but not its nonosteotropic parent cell line LNCaP, has an osteoblastlike phenotype including production of alkaline phosphatase, osteocalcin, osteonectin, bone sialoprotein, osteoprotegerin (OPG), and OPG ligand. Most importantly, the C4-2B cells produced hydroxyapatite mineral in vitro. Furthermore, C4-2B cells expressed high nuclear levels of the bone-specific transcription factor Cbfa1, compared to LNCaP cells, which accounts for their ability to produce bone-specific proteins. Inhibition of Cbfa1, using decoy DNA Cbfa1 response elements, abrogated the ability of C4-2B to produce mineral. Finally, we determined that C4-2B cells express bone morphogenic protein-7, a known inducer of Cbfa1 expression. CONCLUSIONS These data demonstrate a novel mechanism through which prostate cancer cells may directly contribute to the osteoblastic component that characterize their skeletal metastatic lesions. Prostate 47:212–221, 2001. © 2001 Wiley-Liss, Inc.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.